Welcome

Sign out Have a question? We're here to help

Sign out

Veru Inc (VERU)

$3.10 0.00 (0.00%)

9:40 EDT VERU Stock Quote Delayed 20 Minutes

Volume:

Previous Close $3.10

Market Cap 165.89M

PE Ratio -10.33

EPS -0.3

Volume (Avg. Vol.) 5,770

Day's Range 3.07 - 3.15

52-Week Range 1.18 - 4.74

Dividend & Yield N/A (N/A)

VERU Stock Predictions, Articles, and Veru Inc News

From InvestorPlace
From the Web

7 ‘A’-Rated Stocks Under $5 to Buy Now

By Louis Navellier, Editor, Growth Investor Feb 7, 2020

These small-cap stocks to buy are all under $5, but they come from industries and sectors with massive potential.

Veru (VERU) Received its Third Buy in a Row

From Smarter Analyst Feb 27, 2020

After Oppenheimer and Brookline Capital Markets gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from H.C.

Veru Inc. Just Reported And Analysts Have Been Lifting Their Price Targets

From Simply Wall St Feb 17, 2020

As you might know, Veru Inc. (NASDAQ:VERU) just kicked off its latest first-quarter results with some very strong numbers. Sales crushed expectations at US$11m, beating expectations by 21%. Veru reported<div><a class="permalink" href="https://simplywall.st/stocks/us/household/nasdaq-veru/veru/news/veru-inc-just-reported-and-analysts-have-been-lifting-their-price-targets/">Read More...</a></div>

Veru (VERU) Received its Third Buy in a Row

From Smarter Analyst Feb 13, 2020

After Cantor Fitzgerald and Oppenheimer gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from H.C.

Veru (VERU) Received its Third Buy in a Row

From Analyst Ratings Feb 13, 2020

After Cantor Fitzgerald and Oppenheimer gave Veru (NASDAQ: VERU) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Yi Chen reiterated a Buy rating on Veru today and set a price target of $6.00. The company’s shares closed last Monday at $4.32, close to its 52-week high of

The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

From Benzinga Feb 12, 2020

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV)...

Veru EPS misses by $0.03, beats on revenue

From Seeking Alpha Feb 12, 2020

Veru (NASDAQ:VERU): Q1 GAAP EPS of -$0.05 misses by $0.03.Revenue of $10.58M (+66.1% Y/Y) beats by $1.81M.Press Release

Navellier Ratings

Total Grade

Strong Buy

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Welcome

Veru Inc (VERU)

Navellier Ratings

Total Grade

Premium Services

We are always here to help!

Not Yet a Subscriber?

Welcome

Already a subscriber?

Welcome

Veru Inc (VERU)

VERU Stock Predictions, Articles, and Veru Inc News

7 ‘A’-Rated Stocks Under $5 to Buy Now

Veru (VERU) Received its Third Buy in a Row

Veru Inc. Just Reported And Analysts Have Been Lifting Their Price Targets

Veru (VERU) Received its Third Buy in a Row

Veru (VERU) Received its Third Buy in a Row

The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data

Veru EPS misses by $0.03, beats on revenue

Navellier Ratings

Total Grade

Subscriber Sign in